Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Daiichi Sankyo Co., Ltd.
With
Daiichi Sankyo
AstraZeneca
At study start, only Cohort A is active.
If, and when, Cohort B and C become active depends on the assessment of benefit and risk observed in the program.
The sponsor will inform the investigators if, and when, Cohort B and C are active.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has pathologically documented unresectable, recurrent, or metastatic colorectal adenocarcinoma (until sponsor's notification to the study sites, subject must be a RAS/BRAF wild-type cancer)
Has received at least 2 prior regimens of standard treatment
Has measurable disease assessed by the investigator based on RECIST version 1.1.
Has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1
You may not be if
Has a medical history of myocardial infarction within 6 months, symptomatic congestive heart failure
Has a medical history of clinically significant lung disease
Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy
Clareo Health | DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
